Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From PAION AG
The US obtained access to doses that it will donate to low- and low-middle-income countries, Merck & Co. is lining up government purchases of its Phase III drug, and Ocugen will submit a BLA in the US rather than pursue an EUA for Bharat's vaccine. Plus progress and setbacks for COVID-19 therapeutics.
Janssen is the latest big pharma company to gain an approval for a new oral multiple sclerosis therapy in the EU, enhancing the competitiveness of the marketplace, and giving more choice for patients.
Public Company Edition: Roivant’s deal sets its market cap at $7.3bn. Beyond the Werewolf and Vaccitech offerings, more drug developers are slated to go public during the first week of May. And in follow-on offerings, COMPASS Pathways raises $144m and Aldeyra brings in $125m.
Although 2020 was the best year ever for Swiss biotech financing activities, no domestic IPOs were launched by the sector. But introducing the SPAC might change that.
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
- CeNeS Pharmaceuticals plc.